DOCSLIB.ORG

1 2 3 4 5 6 7 8 ABCDEFG First Name Last Name

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 2 3 4 5 6 7 8 ABCDEFG First Name Last Name ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options University of Texas Southwestern Medical 2 Kenneth Altshuler MD Center Dallas Janssen Abbott, Bristol‐Myers Squibb, Eli Lilly, Forest, Janssen, AstraZeneca, Bristol‐ AstraZeneca, Pfizer, Myers Squibb. Eli Lilly, 3 Lori Altshuler MD UCLA Abbott GlaxoSmithKline, Wyeth GlaxoSmithKline Western Psychiatric Institute Shire, Schering‐Plough, Jazz, 4 Boris Birmaher MD Pittsburg, PA Forest Solvay Abbott, Bristol‐Myers Squibb, Elan, GlaxoSmithKline, Janssen, Johnson & Johnson, Abbott, GlaxoSmithKline, Lilly Research, Parke‐Davis, Janssen, Eli Lilly, Lilly Research, Abbott, AstraZeneca, Eli University of Texas Health Robert Wood Johnson and Sanofi‐Synthelabo, UCB Lilly, GlaxoSmithKline, 5 Charles Bowden MD Science Center San Antonio Smith Kline Beecham Pharma, AstraZeneca, Pfizer Janssen AstraZeneca, GlaxoSmithKline, Merck, Organon, Pfizer, Roche, 6 Robert Buchanan MD University of Maryland Janssen, Ortho‐McNeil Solvay, Wyeth Abbott, AstraZeneca, Bristol‐ Myers Squibb, Eli Lilly, Abbott, AstraZeneca, Bristol‐ Abbott, AZ, BMS, Eli Lilly, Janssen, Pfizer, Solvay, Myers Squibb, Eli Lilly, Janssen, Janssen, Pfizer, Alamo, 7 Peter Buckley MD Medical College of Georgia Novartis Merck, Pfizer, Alamo, Novartis AstraZeneca Abbott, AstraZeneca, Merck, Abbott, AstraZeneca, Bristol‐ GlaxoSmithKline, Janssen, Eli Myers Squibb/Otsuka, Eli Lilly, Lilly, Pfizer, Ciba‐Geigy, GlaxoSmithKline, Janssen, Robert Wood Johnson, Teva, Janssen, Robert Wood Case Western Reserve Sandoz, Tap, UCB Pharma, Johnson, Tap, UCB Pharma, 8 Joseph Calabrese MD University, Cleveland Ohio Wyeth Novartis, Parke‐Davis, Shire ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options 9 Caryn Carlson PhD University of Texas Austin University of Washington, (Formerly) Univ Texas Health 10 John Chiles MD Science Center San Antonio Janssen, Eli Lilly AstraZeneca, Janssen, Eli Lilly Ivax, Alkermes, Cortex (Formerly) University of Maryland (Currently) AstraZeneca, Eli Lilly, Janssen, 11 Robert Conley MD Eli Lilly Wyeth, Johnson & Johnson Novartis, Eli Lilly, McNeil, 12 C Keith Conners PhD Duke University Shire, GlaxoSmithKline AstraZeneca, Bristol‐Myers Squibb, Cyberonics, Eli Lilly, Abbott, AstraZeneca, Bristol‐ Forest, Janssen, McNeil, Pfizer, Univ of Texas College of Myers Squibb, Eli Lilly, Forest, Pharmacia, Shire, Corcept 13 Lynn Crismon PharmD Pharmacy Janssen, Pfizer, Shire Therapeutics 14 John Curry PhD Duke University Reach institute University of Texas Southwestern Medical Center Dallas Adjunct prof. And Johnson & Johnson 15 Ella Daly MB MRCemployee GlaxoSmithKline, Wyeth, Corcept, GlaxoSmithKline, Abbott, Eli Lilly, Pfizer, Wyeth, Abbott, Eli Lilly, Pfizer, 16 Charles DeBattista MD Stanford University Cephalon Cephalon Corcept AstraZeneca, Corcept Therapeutics, Forest, Medtronics, Eli Lilly, AstraZeneca, Eli Lilly, Forest, University of Texas Health GlaxoSmithKline, Organon, Neuronetics, Wyeth, Eli Lilly, Pfizer, Wyeth‐ 17 Pedro Delgado MD Science Center San Antonio Wyeth, Forest GlaxoSmithKline, Organon Ayerst Purdue University, (formerly) 18 Ellen Dennehy Phd UTSWMC Dallas ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options University of Texas Eli Lilly, GlaxoSmithKline, Southwestern Medical Forest, Pfizer, Wyeth‐Ayerst, 19 Graham Emslie MD Center Dallas Eli Lilly, Organon, Forest Ortho McNeil New York Dept of Mental 20 Susan Essock PhD Health Aspect Medical, AstraZeneca, Bayer, Biovail, BrainCells, Bristol‐Myers Squibb, Cephalon, Compellis, Cypress Bioscience, Dov, Eli Lilly, EPIX, Abbott, Alkermes, Aspect Forest, GlaxoSmithKline, Medical, AstraZeneca, Bristol‐ Janssen, Jazz, Johnson & Myers Squibb, Cephalon, Eli johson, Knoll, Lundbeck, Lilly, Forest, GlaxoSmithLine, MedAvante, Neuronetics, AstraZeneca, Boehringer‐ Johnson & Johnson, Lichtwer Novartis, Nutrician21, Ingelheim, Bristol‐Myers Pharma, Lorex, Novartis, Organon, PamLab, Pfizer, Squibb, Cephalon, Organon, pamLab, Pfizer, Pharmacia & Upjohn, Compellis, Eli Lilly, Pharmcia & Upjohn, PharmaStar, Phamavite, Forest, GlaxoSmithKline, Pharmavite, Roche, Roche, Sanofi/Synthelabo, MedAvante, Novartis, Sanofi/Synthelabo, Sanofi‐ Sanofi‐Aventis, Spracor, Organon, Pfizer, Massachusetts General Aventis, Spracor, Solvay, Solvay, Somozon, Somerset, PharmaStar, Wyeth‐ 21 Maurizio Fava MD Hospital, Harvard Wyeth‐Ayerst Wyeth‐Ayerst. Ayerst New York Dept of Mental 22 Molly Finnerty MD Health Washington University School of Medicine in St. 23 Barbara Geller MD Louis Solvay, Wyeth New York State Psychiatric Novartis, Eli Lilly, Celltech, 24 Lawrence L Greenhill MD Institute Novartis, Eli Lilly, Ortho McNeil, Janssen ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options Wyeth‐Ayerst, Abbott, AstraZeneca, Bristol‐Myers Cephalon, Forest, Squibb, Forest, GlaxoSmithKline, Janssen, GlaxoSmithKline, Janssen, Eli Ortho McNeil, Eli Lilly, University of Texas Medical Lilly, Novartis, Organon, Novartis, Organon, Pfizer, 25 Robert Hirschfeld MD Branch Galveston Pfizer, shire, UCB Pharma Shire, Solvay, Wyety University of Texas Southwestern Medical 26 Carroll Hughes Phd Center Dallas GlaxoSmithKline Janssen Janssen, UCB Pharma, Janssen, McNeil, Pfizer, Eli Novartis, CMED, McNeil, 27 Peter Jensen MD The Reach Institute Lilly, Novartis, Magellan Otsuka, Shire Eli Lilly 28 David Kahn MD Columbia University Abbott, Bristol‐Myers Squibb, Eli Lilly, Wyeth, Cypress, Bristol‐Myers Squibb, Forest, Cyberonics, Forest, Janssen, Merck, Organon, Pfizer, Organan, Pfizer, Novartis, SmithKlineBeecham, Cephalon, Merck, Pfizer, Pharmacia Upjohn, Wyeth Pharmacia Upjohn, Wyeth 29 Martin Keller MD Brown University Ayerst Ayerst Abbott, AstraZeneca, Bristol‐ Abbott, AstraZeneca, Bristol‐ Myers Squibb, Cephalon, Abbott, AstraZeneca, Myers Squibb, Elan, Eli Lilly, Corcept, Elan, Eli Lilly, Forest, Bristol‐Myers Squibb, Eli GlaxoSmithKline, Janssen, GlaxoSmithKline, Janssen, Jazz, Lilly, GlaxoSmithKline, Novartis, Shire, Solvay, Merck, Novartis, Shire, Solvay, Janssen, Novartis, Pfizer, 30 Terence Ketter MD Stanford University Wyeth Pfizer, UCB Pharma, Wyeth Shire (Formerly) University of Texas Southwestern Medical Center. (Currently) GlaxoSmithKline, Astrazeneca, 31 Robert Kowatch MD Cincinnati Childrens Hospital Bristol‐Myers Squibb Abbott ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options Scott and White Hospital and Clinic, Department of 32 Maria Llana PharmD Psychiatry 33 Molly Lopez Phd University of Texas Bristol‐Myers Squibb, Aspect Medical, Cyberonics, Eli Cyberonics, Eli Lilly, (Formerly) Baylor (Currently) Cyberonics, Eli Lilly, Lilly, Forest, GlaxoSmithKline, GlaxoSmithKline, Forest, 34 Lauren Marangell MD Eli Lilly Neuronetics Medtronics, Novartis, Pfizer Wyeth Bristol‐Myers Squibb, Eli Lilly, Organon, GlaxoSmithKline, Merck, West Los Angeles VA Health AstraZeneca, Janssen, Bristol‐ Otsuka, Pfizer, Solvay, Janssen, 35 Stephen Marder MD Care Center, Calif Myers Squibb, Pfizer Eli Lilly Shire, Eli Lilly, McNeil, Janssen, Eli Lilly, Shire, Bristol‐Myers Cephalon, Abbott, UCB 36 James McCracken MD UCLA Squibb Pharma. AstraZeneca, Bristol‐Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Organon, Pfizer, Sanofi‐ Bristol‐Myers Squibb, Eli 37 Joseph McEvoy MD Duke University Synthelabo GlaxoSmithKline; Eli Lilly, Pfizer Lilly, Janssen, Otsuka Abbott, Almirall, AstraZeneca, Bristol‐Myers Abbott, AstraZeneca, Bristol‐ University of Texas Health Squibb, Eli Lilly, Janssen, Myers Squibb, Eli Lilly, Janssen, 38 Alexander Miller MD Science Center San Antonio Pfizer Pfizer Alexza, AstraZeneca, Bristol‐ AstraZeneca, Bristol‐Myers Myers Squibb, Eli Lilly, Forest, Squibb, Centene, Dainippon GlaxoSmithKline, Janssen Sumitomo, Eli Lilly, Janssen, AstraZeneca, Biovail, University of Texas Health Research Foundation, Oraganon, Pfizer, Solvay, Bristol‐Myers Squibb, Eli 39 Alexander Miller MD Science Center San Antonio Organon, Pfizer InforMedix, Lilly, Janssen, Pfizer Iowa Carver College of 40 Del Miller Md Medicine Eli Lilly Janssen ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options University of Texas Health 41 Troy Moore PharmD Science Center San Antonio Abbott, AstraZeneca, Biovail, Bristol‐Myers Squibb, Corcept, Eli Lilly, Forest, GlaxoSmithKline, Novartis, Eli Lilly, Janssen, Organon, Orexigen, Organon, Pfizer, 42 Craig Nelson MD Yale University Pfizer Janssen, Shire, Wyeth Abbott, Bristol‐Myers Squibb, Eli Lilly, Genaissance, GlaxoSmithKline, Jazz, AstraZeneca, Bristol‐Myers Innapharma, Janssen‐Cilag, Squibb, Cederroth, Neuronetics, Novartis, Cyberonics, Eli Lilly, Forest, Organon, Pfizer, Sepracor, Bristol‐Myers Squibb, GlaxoSmithKline, Lichtwer, Shire, Somerset, Sumitomo, Cyberonics, Eli Lilly, Massachusetts General Millenium, Organon, Pfizer, Wyeth, Cyberonics, Shire, Forest, GlaxoSmithKline, 43 Andrew Nierenberg MD Hospital Wyeth Cederroth, Janssen Organon, Wyeth University of Texas Southwestern Medical 44 Glen Pearson MD Center University of Texas Medical Eli Lilly, GlaxoSmithKline, 45 Teresa Pigott
Load more

Recommended publications
  • Print Layout 1
    TECHNICAL PROGRAM Monday, March 19 5:00 – 8:00 pm Welcome Reception Tuesday, March 20 8:00 – 10:00 Session 1: Setting the Conference Context and Drivers Chair: Geoff Slaff (Amgen) Roger Perlmutter (Amgen) Conquering the Innovation Deficit in Drug Discovery Helen Winkle (CDER, FDA) Regulatory Modernization 10:00 – 10:30 Break Vendor and poster review 10:30 – 12:30 Session 2: Rapid Cell Line Development and Improved Expression System Development Chairs: Timothy Charlebois (Wyeth) and John Joly (Genentech) Amy Shen (Genentech) Stable Antibody Production Cell-Line Development with an Improved Selection Process and Accelerated Timeline Mark Leonard (Wyeth) High-Performing Cell-Line Development within a Rapid and Integrated Platform Process Control Pranhitha Reddy (Amgen) Applying Quality-by-Design to Cell Line Development Lin Zhang (Pfizer) Development of a Fully-Integrated Automated System for High-Throughput Screening and Selection of Single Cells Expressing Monoclonal Antibodies 12:30 – 2:00 Lunch Vendor and poster review 2:00 – 4:30 Session 3: High-Throughput Bulk Process Development Chairs: Brian Kelley (Wyeth) and Jorg Thommes (Biogen Idec) Colette Ranucci (Merck) Development of a Multi-Well Plate System for High-Throughput Process Development Min Zhang (SAFC Biosciences) CHO Media Library – an Efficient Platform for Rapid Development and Optimization of Cell Culture Media Supporting High Production of Pharmaceutical Proteins in Chinese Hamster Ovary Cells Nigel Titchener-Hooker The Use of Ultra-Scale-Down Approaches to Enable Rapid Investigation
    [Show full text]
  • XCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 (State or other jurisdiction of (I.R.S. Employer Identification No) incorporation or organization) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices) (Zip code) (914) 347-7000 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: None (Title of Class) Securities registered pursuant to Section 12(g) of the Act: Common Stock - par value $.001 per share (Title of Class) Preferred Share Purchase Rights expiring October 18, 2006 (Title of Class) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /X/ No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (ss. 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Virginia: in the Circuit Court of Pittsylvania County
    VIRGINIA: IN THE CIRCUIT COURT OF PITTSYLVANIA COUNTY PITTSYLVANIA COUNTY, Plaintiff, v. PURDUE PHARMA, L.P.; PURDUE PHARMA, INC.; THE PURDUE FREDERICK COMPANY, INC.; RHODES PHARMACEUTICALS, L.P.; ABBOTT LABORATORIES; ABBOTT LABORATORIES, INC.; MALLINCKRODT PLC; MALLINCKRODT LLC; ENDO HEALTH SOLUTIONS, INC; ENDO PHARMACEUTICALS, INC.; PAR Case No. CL18 - __________ PHARMACEUTICAL COMPANIES, INC.; PAR PHARMACEUTICAL, INC.; TEVA Jury Trial Demanded PHARMACEUTICALS USA, INC.; CEPHALON, INC.; BARR LABORATORIES, INC.; JANSSEN PHARMACEUTICALS, INC.; ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICA, INC.; WATSON LABORATORIES, INC.; ALLERGAN PLC; ACTAVIS PHARMA, INC.; ACTAVIS, LLC; INSYS THERAPEUTICS, INC.; KVK-TECH, INC.; AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; AMNEAL PHARMACEUTICALS, INC.; AMNEAL PHARMACEUTICALS OF NEW YORK, LLC; MYLAN PHARMACEUTICALS, INC.; MCKESSON CORPORATION; MCKESSON MEDICAL-SURGICAL INC.; CARDINAL HEALTH, INC.; AMERISOURCEBERGEN DRUG CORPORATION; HENRY SCHEIN, INC.; GENERAL INJECTABLES & VACCINES, INC.; INSOURCE, INC.; CVS HEALTH CORPORATION; CVS PHARMACY, INC.; CVS TN DISTRIBUTION, L.L.C.; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.; EXPRESS SCRIPTS HOLDING COMPANY; EXPRESS SCRIPTS, INC; CAREMARK RX, L.L.C.; CAREMARKPCS HEALTH, L.L.C.; CAREMARK, L.L.C.; UNITEDHEALTH GROUP INCORPORATED; OPTUM, INC.; OPTUMRX, INC.; and DOES 1-100, Defendants. PLAINTIFF’S ORIGINAL COMPLAINT Plaintiff, Pittsylvania County, Virginia, by and through the undersigned attorneys, (hereinafter “Plaintiff,” “Pittsylvania
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • Moderna Vaccine Day Presentation
    Zika Encoded VLP mRNA(s) RSV CMV + EBV SARS-CoV- RSV-ped 2 Flu hMPV/PIV3 H7N9 Encoded mRNA(s) Ribosome Protein chain(s) First Vaccines Day April 14, 2020 © 2020 M oderna Therapeutics Forward-looking statements and disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning; the impact of the SARS-CoV-2 pandemic on the Company’s clinical trials and operations; the timing and finalization of a dose-confirmation Phase 2 study and planning for a pivotal Phase 3 study for mRNA-1647; the status and outcome of the Phase 1 clinical trial for mRNA-1273 being conducted by NIH; the next steps and ultimate commercial plan for mRNA-1273; the size of the potential market opportunity for mRNA-1273; the size of the potential commercial market for novel vaccines produced by Moderna or others; the potential peak sales for the Company’s wholly-owned vaccines; the probability of success of the Company’s vaccines individually and as a portfolio; and the ability of the Company to accelerate the research and development timeline for any individual product or the platform as a whole. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
    [Show full text]
  • Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc Mylotarg
    Mylotarg FDA ODAC Briefing Document 11 July 2017 WYETH PHARMACEUTICALS INC., A SUBSIDIARY OF PFIZER INC MYLOTARG (gemtuzumab ozogamicin; PF-05208747) In combination with chemotherapy for the treatment of previously untreated de novo CD33-positive acute myeloid leukemia and as monotherapy for the treatment of CD33-positive acute myeloid leukemia in first relapse FDA ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT (BLA 761060) Meeting Date: 11 July 2017 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 090177e18c1aa788\Approved\Approved On: 12-Jun-2017 13:05 (GMT) Page 1 Mylotarg FDA ODAC Briefing Document 11 July 2017 TABLE OF CONTENTS TABLE OF CONTENTS...........................................................................................................2 LIST OF TABLES.....................................................................................................................5 LIST OF FIGURES ...................................................................................................................6 1. EXECUTIVE SUMMARY .................................................................................................7 1.1. Introduction..............................................................................................................7 1.2. Rationale for Mylotarg Dosing Regimens ...............................................................8 1.3. Mylotarg in Patients With Previously Untreated De Novo AML............................9 1.4. Mylotarg in Patients With AML in First Relapse..................................................11
    [Show full text]
  • Complaint, “Chronic Pain” Means Non-Cancer Pain Lasting Three Months Or Longer
    TABLE OF CONTENTS Page I. INTRODUCTION ...............................................................................................................1 II. JURISDICTION AND VENUE ..........................................................................................8 III. PARTIES .............................................................................................................................8 A. Plaintiff ....................................................................................................................8 B. Defendants ...............................................................................................................9 IV. FACTUAL ALLEGATIONS ............................................................................................14 A. Defendants Used Multiple Avenues To Disseminate Their False And Deceptive Statements About Opioids. ...................................................................14 1. Defendants spread and continue to spread their false and deceptive statements through direct marketing of their branded opioids. .......................................................................................................15 2. Defendants used a diverse group of seemingly independent third parties to spread false and deceptive statements about the risks and benefits of opioids.................................................................17 a. Key Opinion Leaders (“KOLs”) ....................................................19 (1) Russell Portenoy ................................................................20
    [Show full text]
  • Ipo Virtual Annual Meeting Sept
    PATENTS | TRADEMARKS | COPYRIGHTS TRADE SECRETS | INDUSTRIAL DESIGNS IPO VIRTUAL ANNUAL MEETING SEPT. 21-24, 2020 IPO.ORG/AM2020 KEYNOTE SPEAKERS 30+ EDUCATION POPPY CRUM SESSIONS PhD, Chief Scientist, Dolby Laboratories ANTÓNIO CAMPINOS President, European Patent Office IP EXPO #IPOAM20 ANDREI IANCU Under Secretary of Commerce for Intellectual Property and Director United States Patent and Trademark Office KASUTANI NETWORKING TOSHIHIDE Commissioner, Japan Patent Office CONNECT ENGAGE LEARN IPO VIRTUAL ANNUAL MEETING | SEPT. 21-24, 2020 TABLE OF CONTENTS ANNUAL MEETING STANDING IP COMMITTEES 4 COMMITTEE BUSINESS MEETINGS 5 PROGRAM AT-A-GLANCE 6 GENERAL SESSIONS 8 WORKSHOPS 11 PATENT SESSIONS 12 TRADEMARK/COPYRIGHT SESSIONS 17 INDUSTRIAL DESIGNS SESSIONS 20 OPERATIONS SESSIONS 21 SPONSORS 22 VIRTUAL IP EXPO 23 NETWORKING 24 REGISTRATION AND MEETING POLICIES 27 REGISTRATION FORM 28 IPO VIRTUAL ANNUAL MEETING | SEPT. 21-24, 2020 ANNUAL MEETING We are looking forward to bringing our members together in a new and innovative way this year for the 2020 Virtual Annual PROGRAM COMMITTEE Meeting on a secure and engaging virtual platform. The IPO Annual Meeting offers a mix of educational programs LEADERSHIP: featuring leaders in the IP industry, committee meetings, networking opportunities, exhibits, and more. This must-attend CHAIR: event brings together IP professionals from around the world Steve Caltrider, Eli Lilly and Co. to discuss strategies, trends, and best practices. More than VICE CHAIR FOR PATENTS: 30 education sessions will be offered on patents, trademarks, Scott Barker, Micron Technology, Inc. copyrights, industrial designs, and – new this year – operations. In addition to the sessions planned by IPO’s Program VICE CHAIR FOR TRADEMARKS: Committee, several sessions are being organized by IPO’s Colette Durst, 3M Innovative Properties Co.
    [Show full text]
  • Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
    Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers August 4, 2009 THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab)]. This safety review was the subject of an FDA Early Communication in June 2008 pertaining to cases of malignancy in pediatric patients exposed to a TNF blocker. As a result of this review, the FDA has required strengthened warnings about the occurrence of lymphoma and other cancers in children and young adults using these medicines. AMGEN AND WYETH STATEMENT: Amgen and Wyeth believe that ENBREL continues to offer a favorable benefit-risk relationship for patients with the diseases for which it is indicated to treat, including moderate to severe Juvenile Idiopathic Arthritis (JIA). JIA can be a serious and potentially debilitating condition. Amgen will work with the FDA to update the U.S. Prescribing Information, and Medication Guide for ENBREL as described in the FDA communication which can be read at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm. In addition, Amgen and Wyeth will communicate the revised product labeling to both physicians and patients. ENBREL was first approved for JIA in the U.S. in 1999. It is estimated through postmarketing data that approximately 13,847 pediatric patients have been treated with ENBREL globally through February 2009, accounting for approximately 44,600 patient-years of exposure.
    [Show full text]
  • Bristol Myers
    United States Court of Appeals for the Federal Circuit ______________________ BRISTOL-MYERS SQUIBB COMPANY, Plaintiff-Appellant, v. TEVA PHARMACEUTICALS USA, INC., Defendant-Appellee. ______________________ 2013-1306 ______________________ Appeal from the United States District Court for the District of Delaware in No. 10-CV-0805, Magistrate Judge Christopher J. Burke. ______________________ Decided: June 12, 2014 ______________________ WILLIAM F. LEE, Wilmer Cutler Pickering Hale and Dorr LLP, of Boston, Massachusetts, argued for plaintiff- appellant. With him on the brief were LAUREN B. FLETCHER and ANDREW J. DANFORD; AMY K. WIGMORE and THOMAS G. SAUNDERS, of Washington, DC. Of counsel on the brief were PAUL BERGHOFF, ALISON J. BALDWIN, and JOSHUA R. RICH, McDonnell Boehnen Hulbert & Berghoff LLP, of Chicago, Illinois. GEORGE C. LOMBARDI, Winston & Strawn LLP, of Chi- cago, Illinois, argued for defendant-appellee. With him on the brief were LYNN MACDONALD ULRICH, IVAN M. 2 BRISTOL-MYERS SQUIBB COMPANY v. TEVA PHARMACEUTICALS USA, INC. POULLAOS, JULIA MANO JOHNSON, and WILLIAM P. FERRANTI. ______________________ ∗ Before PROST, Chief Judge, PLAGER and CHEN, Circuit Judges. CHEN, Circuit Judge. This patent infringement case concerns a drug for the treatment of hepatitis B. After a four-day bench trial, the United States District Court for the District of Delaware found claim 8 of U.S. Patent No. 5,206,244 (’244 patent) invalid as obvious. We affirm the district court’s invalidi- ty judgment for the reasons that follow. I. Appellant Bristol-Myers Squibb Co. (BMS) owns the ’244 patent. Claim 8 of the ’244 patent is directed to a nucleoside analog composed of two regions: a carbocyclic ring and a guanine base.
    [Show full text]
  • Mvx List.Pdf
    MVX_CODE manufacturer_name Notes status last updated date manufacturer_id AB Abbott Laboratories includes Ross Products Division, Solvay Inactive 16-Nov-17 1 ACA Acambis, Inc acquired by sanofi in sept 2008 Inactive 28-May-10 2 AD Adams Laboratories, Inc. Inactive 16-Nov-17 3 ALP Alpha Therapeutic Corporation Inactive 16-Nov-17 4 AR Armour part of CSL Inactive 28-May-10 5 AVB Aventis Behring L.L.C. part of CSL Inactive 28-May-10 6 AVI Aviron acquired by Medimmune Inactive 28-May-10 7 BA Baxter Healthcare Corporation-inactive Inactive 28-May-10 8 BAH Baxter Healthcare Corporation includes Hyland Immuno, Immuno International AG,and North American Vaccine, Inc./acquired somInactive 16-Nov-17 9 BAY Bayer Corporation Bayer Biologicals now owned by Talecris Inactive 28-May-10 10 BP Berna Products Inactive 28-May-10 11 BPC Berna Products Corporation includes Swiss Serum and Vaccine Institute Berne Inactive 16-Nov-17 12 BTP Biotest Pharmaceuticals Corporation New owner of NABI HB as of December 2007, Does NOT replace NABI Biopharmaceuticals in this codActive 28-May-10 13 MIP Emergent BioSolutions Formerly Emergent BioDefense Operations Lansing and Michigan Biologic Products Institute Active 16-Nov-17 14 CSL bioCSL bioCSL a part of Seqirus Inactive 26-Sep-16 15 CNJ Cangene Corporation Purchased by Emergent Biosolutions Inactive 29-Apr-14 16 CMP Celltech Medeva Pharmaceuticals Part of Novartis Inactive 28-May-10 17 CEN Centeon L.L.C. Inactive 28-May-10 18 CHI Chiron Corporation Part of Novartis Inactive 28-May-10 19 CON Connaught acquired by Merieux Inactive 28-May-10 21 DVC DynPort Vaccine Company, LLC Active 28-May-10 22 EVN Evans Medical Limited Part of Novartis Inactive 28-May-10 23 GEO GeoVax Labs, Inc.
    [Show full text]